Fox Run Management L.L.C. Invests $286,000 in Castle Biosciences, Inc. (NASDAQ:CSTL)

Fox Run Management L.L.C. purchased a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,716 shares of the company’s stock, valued at approximately $286,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its holdings in Castle Biosciences by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after buying an additional 604 shares in the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Castle Biosciences by 3.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company’s stock valued at $690,000 after acquiring an additional 845 shares in the last quarter. Truist Financial Corp lifted its holdings in Castle Biosciences by 4.6% in the 4th quarter. Truist Financial Corp now owns 21,303 shares of the company’s stock worth $568,000 after purchasing an additional 928 shares during the last quarter. Bailard Inc. boosted its position in Castle Biosciences by 12.5% during the fourth quarter. Bailard Inc. now owns 9,900 shares of the company’s stock worth $264,000 after purchasing an additional 1,100 shares during the period. Finally, Quest Partners LLC grew its holdings in Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after purchasing an additional 1,522 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

CSTL has been the subject of a number of analyst reports. Stephens restated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Robert W. Baird boosted their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences currently has a consensus rating of “Buy” and a consensus target price of $40.00.

Insiders Place Their Bets

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the completion of the transaction, the director now owns 1,425 shares of the company’s stock, valued at $41,524.50. This represents a 84.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Derek J. Maetzold sold 2,715 shares of Castle Biosciences stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $29.62, for a total value of $80,418.30. Following the sale, the insider now directly owns 82,047 shares in the company, valued at $2,430,232.14. The trade was a 3.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,204 shares of company stock worth $1,055,988 in the last ninety days. Insiders own 7.20% of the company’s stock.

Castle Biosciences Trading Up 0.1 %

Shares of CSTL stock opened at $20.10 on Friday. The firm has a market capitalization of $562.94 million, a P/E ratio of 100.51 and a beta of 0.98. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The firm’s fifty day simple moving average is $24.29 and its 200 day simple moving average is $28.07. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.